Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Trial of KB004 in Patients With Glioblastoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03374943
Recruitment Status : Recruiting
First Posted : December 15, 2017
Last Update Posted : June 17, 2019
Sponsor:
Collaborator:
Humanigen, Inc.
Information provided by (Responsible Party):
Olivia Newton-John Cancer Research Institute

Brief Summary:

This is a study of drug KB004 in patients with recurrent glioblastoma (GBM). Eligible patients with measurable tumours will receive an initial trace (5mg) dose of zirconium labelled KB004 (89ZrKB004) on day 1 followed by sequential Positron emission tomography (PET) imaging over 1 week to determine its biodistribution into GBM and normal tissues. Safety assessments and pharmacokinetic (movement of drug) sampling will also be undertaken over this time. On Day 8, patients commence weekly KB004 infusions over 2 hours with standard premedications. Three cohorts are planned in this study (3.5mg/kg, 5.25 mg/kg, 7.9 mg/kg; additional dose levels may be explored based on toxicity, efficacy and biodistribution data as determined by the safety monitoring committee). On day 36, patients receive both 89ZrKB004 and KB004, allowing assessment of receptor occupancy to guide recommended phase two dose (RPTD) determination. Response rate (RANO) and survival data will be collected and patients benefiting may continue KB004 treatment until disease progression. Primary objective: to determine the toxicity and recommended phase two dose (RPTD) of KB004 in patients with advanced Glioblastoma (GBM).

Secondary objectives: to determine the biodistribution and pharmacokinetics of 89ZrKB004; to determine frequency of EphA3 (ephrin receptor A3) positive glioblastoma in archival specimens and by 89ZrKB004 scans, and correlate with known biomarkers; to describe response rates per RANO criteria (Response Assessment in Neuro-Oncology Criteria) and pharmacodynamics following KB004 infusion; Exploratory objectives: to perform exploratory analysis between clinical outcomes and biodistribution/Pharmacokinetics (PK)/pharmacodynamics (PD) data, including from matched biopsies.


Condition or disease Intervention/treatment Phase
Glioblastoma Drug: KB004 Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 12 participants
Intervention Model: Sequential Assignment
Intervention Model Description: The study will use a 3+3 methodology for the 3 dose levels proposed. In brief, three patients will be recruited per dose level. In the absence of any Dose Limiting toxicity (DLT) in a cohort, escalation to the next dose level will occur.
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I Safety and Bioimaging Trial of KB004 in Patients With Glioblastoma
Actual Study Start Date : December 5, 2017
Estimated Primary Completion Date : October 22, 2020
Estimated Study Completion Date : April 22, 2021

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: KB004 dose escalation
Patients will be entered at each KB004 dose level sequentially until 3-6 patients are evaluable for safety. Three sequential cohorts are planned in this study (3.5mg/kg, 5.25 mg/kg, 7.9 mg/kg) Additional dose levels may be explored based on the emerging data in the study.
Drug: KB004
KB004 is a recombinant, non-fucosylated, IgG1κ (human f-allotype) monoclonal antibody targeting the extracellular ligand binding domain of the EphA3 (ephrin receptor) tyrosine kinase




Primary Outcome Measures :
  1. Number of Participants With KB004 Treatment-Related Adverse Events as Assessed using CTCAE v4.0. To determine the maximum tolerated dose (MTD). [ Time Frame: 0-24 months ]

    Three patients are recruited per dose level, 3 dose levels. Dose limiting toxicity (DLT) defined as Grade 4 neutropenia > 7 day duration Grade 3 or 4 febrile neutropenia Grade 3 or 4 thrombocytopenia > 7 day duration Grade 4 anaemia > 7 day duration Grade 3 or 4 non-hematologic adverse events which do not resolve within 48 hours with maximal supportive care.

    Grade 4 or recurrent Grade 3 infusion reactions despite maximal supportive care and dose reductions Significant intracranial haemorrhage not reasonably attributed to other cause More than 14 days of treatment delay due to attributable toxicity Other toxicities as determined by the investigators. In the absence of any dose limiting toxicity in a cohort, escalate to the next dose level. If one DLT is seen in the first three patients of a cohort, an additional three patients will be recruited to that cohort. If two or more DLT's are seen in any cohort, that cohort will be deemed the maximum tolerated dose.



Secondary Outcome Measures :
  1. Biodistribution of 89Zr-KB004 [ Time Frame: 0-24 months ]
    Eligible patients with measurable tumours will receive an initial trace (5mg) dose of zirconium labelled KB004 (89Zr-KB004) on day 1 followed by sequential Positron emission tomography, or PET imaging over 1 week to determine its biodistribution into GBM and normal tissues, frequency of EphA3 (ephrin type-A receptor 3) expression in glioblastoma (GBM) and quantitative tumor antibody uptake.

  2. Response rates following KB004 infusion [ Time Frame: 0-24 months ]
    Response Assessment in Neuro-Oncology criteria will be used to interpret MRI (magnetic resonance imaging) scans

  3. Plasma concentration versus time (Serum half life) of 89Zr-KB004 [ Time Frame: 0-43 days ]
    Pharmacokinetics (plasma concentration versus time) of 89Zr-KB004 will be determined using gamma well counting of the Zirconium in the samples at various timepoints-Day 1 89Zr-KB004 infusion: pre-infusion, 5min, 1 hour, 2 hours, 4 hours and 24 hours post infusion, then Day 3 or 4, 6 or 7. PK (Pharmacokinetics) timepoints Day 89Zr-KB004 infusion: pre-infusion, 5min, 1 hour, 2 hours, 4 hours and 24 hours post infusion then Day 39 or 40 and Day 42 or 43.

  4. Cmax of 89Zr-KB004 [ Time Frame: 0-43 days ]
    Pharmacokinetics (Cmax) of 89Zr-KB004 will be determined using gamma well counting of the Zirconium in the samples at various timepoints-Day 1 89Zr-KB004 infusion: pre-infusion, 5min, 1 hour, 2 hours, 4 hours and 24 hours post infusion, then Day 3 or 4, 6 or 7. PK (Pharmacokinetics) timepoints Day 89Zr-KB004 infusion: pre-infusion, 5min, 1 hour, 2 hours, 4 hours and 24 hours post infusion then Day 39 or 40 and Day 42 or 43.


Other Outcome Measures:
  1. clinical outcomes via RANO criteria (Response Assessment in Neuro-Oncology Criteria) [ Time Frame: 0-24 Months ]
    describe response rates using Response Assessment in Neuro-Oncology Criteria to interpret MRI (magnetic resonance imaging) scans

  2. Biodistribution via PET (Positron-emission tomography) [ Time Frame: 0-43 days ]
    89Zr-KB004 Positron emission tomography imaging will be used



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Adults (greater than or equal to 18 years of age) with histologically proven glioblastoma
  • Evidence of progressive glioblastoma (if within 3 months of radiotherapy, then progression outside of radiotherapy field is required)
  • Measurable disease by RANO (Response Assessment in Neuro-Oncology Criteria)
  • ECOG (Eastern Cooperative Oncology Group score) 0 to 1
  • Expected survival more than 3 months
  • Steroid dose less than 2.5 mg per day dexamethasone equivalents and stable or reducing for 1 week prior to day 1
  • Archived (formalin fixed paraffin embedded) tissue or frozen tumour tissue or consent to obtain a fresh tumour biopsy at enrolment is required.
  • Adequate organ function. Out of range values that are not clinically significant will be permitted, except for the following laboratory parameters which must be within the ranges specified
  • Neutrophils greater than or equal to 1.5 x 109 per L
  • Platelets greater than or equal to 100 x 109 per L
  • International Normalised Ratio less than or equal to 1.4
  • Serum Aspartate aminotransferase and Alanine aminotransferase less than or equal to 2.5 x ULN (upper limit of normal)
  • Serum bilirubin less than or equal to 1.5 x ULN (upper limit of normal)

Exclusion Criteria:

  • Evidence of infratentorial, extracranial or leptomeningeal disease
  • More than one prior systemic therapy for progressive disease or prior Steriotactic radiosurgery (SRS) to sites of GB (glioblastoma).
  • Prior treatment with bevacizumab or gliadel wafers
  • Evidence of current or prior intracranial hemorrhage
  • Need for anti-platelet or anti-coagulant drugs
  • Use of anti-cancer therapy including craniotomy, chemotherapy, immunotherapy, radiotherapy, or any investigational therapy within 28 days prior to Study Day 1
  • History of major immunologic reaction to any immunoglobulin G containing agent
  • Medical conditions which place the subject at an unacceptably high risk
  • Subject is pregnant, lactating or unwilling or unable to use adequate contraception

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03374943


Contacts
Layout table for location contacts
Contact: Jodie Palmer, PhD 0394963573 trials@onjcri.org.au
Contact: Fiona Scott 0394963573 ethics@onjcri.org.au

Locations
Layout table for location information
Australia, Queensland
Royal Brisbane and Women's Hospital Not yet recruiting
Brisbane, Queensland, Australia, 4029
Contact: Po-ling Inglis    +6173646 8111    Po-ling.inglis@health.qld.gov.au   
Principal Investigator: Po-ling Inglis         
Australia, Victoria
Austin Health Recruiting
Heidelberg, Victoria, Australia, 3078
Contact: Gan Hui, MBBS, PhD    +61394969925    hui.gan@austin.org.au   
Principal Investigator: Hui Gan         
Sub-Investigator: Andrew Scott         
Sponsors and Collaborators
Olivia Newton-John Cancer Research Institute
Humanigen, Inc.
Investigators
Layout table for investigator information
Principal Investigator: Hui Gan Austin Health

Layout table for additonal information
Responsible Party: Olivia Newton-John Cancer Research Institute
ClinicalTrials.gov Identifier: NCT03374943     History of Changes
Other Study ID Numbers: ONJ2017-002
First Posted: December 15, 2017    Key Record Dates
Last Update Posted: June 17, 2019
Last Verified: November 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Glioblastoma
Astrocytoma
Glioma
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Antibodies, Monoclonal
Immunologic Factors
Physiological Effects of Drugs